Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This trial aims to evaluate the efficacy, safety and tolerability of valbenazine, titrated to
the subject's optimal dose of 40mg or 80mg, administered once daily, for 12 weeks, for the
treatment of trichotillomania (TTM) in a double blind placebo controlled design study. After
week 12, subjects will begin a 12-week, open-label portion of the study. During the
open-label portion of the study, all subjects will receive the study drug at their optimal
dose. The primary endpoint of these studies will be the change from baseline of placebo vs.
active scores utilizing the Massachusetts General Hospital Hairpulling Scale (MGH-HPS) at the
end of Week 12.